Literature DB >> 30483813

Biological role of metabolic reprogramming of cancer cells during epithelial‑mesenchymal transition (Review).

Mingzhe Li1, Xin Bu1, Bolei Cai2, Ping Liang3, Kai Li4, Xuan Qu5, Liangliang Shen1.   

Abstract

Epithelial‑mesenchymal transition (EMT) is required for the distant metastasis of tumors. The degree of tumor malignancy increases as EMT progresses. Notably, the biology of tumor cells differs from that of normal cells, with regards to characteristics and energy metabolism mechanisms; abnormal glucose metabolism, excessive accumulation of fatty acids and other metabolic disorders occur in metastatic tumors. Previous studies have confirmed that the regulation of tumor cell metabolism can affect tumor metastasis and some findings have resulted in novel clinical applications. The present review aimed to provide a basis for treatments targeting the tumor EMT process and metabolic reprogramming.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30483813     DOI: 10.3892/or.2018.6882

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  9 in total

1.  Zoledronic acid-loaded lipidic nanoparticles enhance apoptosis and attenuate invasiveness by inhibiting epithelial to mesenchymal transition (EMT) in HepG2 cancer cells.

Authors:  Mehdi Sabzichi; Omolbanin Oladpour; Jamal Mohammadian; Mohsen Rashidi; Mahla Hosseinzadeh; Alireza Mardomi; Bahman Ramezani; Marjan Ghorbani; Fatemeh Ramezani
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-09-30       Impact factor: 3.000

2.  Downregulation of Crystallin Lambda 1 is a New Independent Prognostic Marker in Clear Cell Renal Cell Carcinoma.

Authors:  Lingsong Feng; Guodong Ding; Yang Zhou; Haiyuan Zhu; Huiming Jiang
Journal:  Pharmgenomics Pers Med       Date:  2022-10-10

3.  Investigation of the effects of downregulation of jumping translocation breakpoint (JTB) protein expression in MCF7 cells for potential use as a biomarker in breast cancer.

Authors:  Madhuri Jayathirtha; Anca-Narcisa Neagu; Danielle Whitham; Shelby Alwine; Costel C Darie
Journal:  Am J Cancer Res       Date:  2022-09-15       Impact factor: 5.942

4.  OGDH promotes the progression of gastric cancer by regulating mitochondrial bioenergetics and Wnt/β-catenin signal pathway.

Authors:  Xin Lu; Nan Wu; Wanli Yang; Jia Sun; Kemin Yan; Jing Wu
Journal:  Onco Targets Ther       Date:  2019-09-12       Impact factor: 4.147

5.  Downregulation of PPA2 expression correlates with poor prognosis of kidney renal clear cell carcinoma.

Authors:  Wenbiao Zhu; Huiming Jiang; Shoucheng Xie; Huanqin Xiao; Qinghua Liu; Nanhui Chen; Pei Wan; Shanming Lu
Journal:  PeerJ       Date:  2021-09-06       Impact factor: 2.984

6.  Identification of IMPA2 as the hub gene associated with colorectal cancer and liver metastasis by integrated bioinformatics analysis.

Authors:  Liuli Wang; Deming Liu; Shuo Liu; Tianyi Liao; Yajun Jiao; Xianglai Jiang; Yongfeng Wang; Yaqiong Chen; Haizhong Ma; Hui Cai
Journal:  Transl Oncol       Date:  2022-04-26       Impact factor: 4.803

7.  AUP1 regulates lipid metabolism and induces lipid accumulation to accelerate the progression of renal clear cell carcinoma.

Authors:  Chen Chen; Wei Zhao; Xingxing Lu; Yunbo Ma; Peizhi Zhang; Zicheng Wang; Zilian Cui; Qinghua Xia
Journal:  Cancer Sci       Date:  2022-06-27       Impact factor: 6.518

8.  Identification and validation of an immune signature associated with EMT and metabolic reprogramming for predicting prognosis and drug response in bladder cancer.

Authors:  Zhao Zhang; Yongbo Yu; Peng Li; Meilan Wang; Wei Jiao; Ye Liang; Haitao Niu
Journal:  Front Immunol       Date:  2022-07-25       Impact factor: 8.786

9.  UDP-glucose dehydrogenase expression is upregulated following EMT and differentially affects intracellular glycerophosphocholine and acetylaspartate levels in breast mesenchymal cell lines.

Authors:  Qiong Wang; Sigurdur Trausti Karvelsson; Freyr Johannsson; Arnar Ingi Vilhjalmsson; Lars Hagen; Davi de Miranda Fonseca; Animesh Sharma; Geir Slupphaug; Ottar Rolfsson
Journal:  Mol Oncol       Date:  2022-02-03       Impact factor: 7.449

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.